Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
LIVED EXPERIENCE: Spontaneous Coronary Artery Dissection (SCAD)
Jen O’Neill is a Social Work Program Manager and mother of two from the Central Coast, NSW.
At 36, she experienced her first spontaneous coronary artery dissection (SCAD) heart attack and has since survived two further SCADs before age 43.
-
Improving access to osteopathic services and integrated care models
The Chief Executive Officer of Osteopathy Australia, Antony Nicholas spoke with Australian Health Journal about:
– Involvement in the Strengthening Medicare Task Force
– The unique skills osteopaths have that can address the chronic disease burden
– Current workforce issues around osteopaths and if enough are coming through via student placements
– How uploading data to My Health Record by osteopaths could assist team-based care of patients
– How the value of osteopaths in Residential Aged Care Facilities (RACFs) could be better understood and better access for residents
– The recommendations around aged care access to allied health services, including osteopathy
– The recommendations around consumer access to osteopaths and GP referrals
– Other osteopathy recommendations in the upcoming Federal BudgetIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
HEALTH CARE BRIEF: Myopia progression in children
Myopia progression in children – Incidence rates, prevalence, risks, symptoms and treatment options
